



FOR IMMEDIATE RELEASE

## **Distribution Agreement signed to market Lercanidipine tablets in Hong Kong and Macau**

(Hong Kong, 30 December 2009) - Lee's Pharmaceutical Holdings Limited (GEM Stock: 8221; Website: [www.leespharm.com](http://www.leespharm.com)) today announced that the Group has signed a License and Supply Agreement with Recordati Ireland Limited ("Recordati"), a European well-known pharmaceutical group for the distribution and marketing of Zanidip<sup>®</sup>-Lercanidipine 10mg tablets, throughout Hong Kong and Macau.

Zanidip<sup>®</sup> (Lercanidipine) belongs to a group of medicines called Calcium Channel Blockers (CCBs) which is widely prescribed for the treatment of hypertension. Zanidip<sup>®</sup> (lercanidipine) was firstly marketed in February 2002 in Australia, as a dihydropyridine (DHPs) with an intrinsic long-acting hypertensive effect which exhibits a slow onset of action to help to avoid reflex tachycardia. It is effective in reducing blood pressure over a 24-hour period with once-daily dosing. Lercanidipine is effective across a wide range of patient groups, including the elderly as well as younger patients and diabetic patients with hypertension. It has equivalent antihypertensive efficacy to many other agents and is effective as initial monotherapy or in combination. The efficacy and tolerability profiles of lercanidipine make it a suitable choice for treating hypertension in a wide range of affected patients with less peripheral oedema than some other CCBs at equivalent antihypertensive doses.

Hypertension is an important cardiovascular risk factor and a major health problem worldwide. The prevalence of hypertension in Hong Kong has been reported to exceed 27%. The public health costs of hypertension are substantial and represent an important area of health service. In the light of increasing prevalence of hypertension among Chinese, the favorable efficacy and safety profile of lercanidipine could be a preferable choice for antihypertensive treatment across a broad range of patients.

"We are extremely pleased with our partnership with Recordati, and are excited about the opportunity to work on its product in Hong Kong," stated Dr. Benjamin Li, the Chief Executive Officer of the Group. "The signing of this agreement is yet another successful effort of the Group to enrich its product pipeline and to broaden its revenue base."

### About RECORDATI

**Recordati**, established in 1926, is a European pharmaceutical group, listed on the Italian Stock Exchange, dedicated to the research, development, manufacturing and marketing of pharmaceuticals, with headquarters in Milan, Italy, operations in the main European countries, and a total staff of over 2,950. A European field force of over 1,450 medical representatives promotes a wide range of innovative pharmaceuticals, both proprietary and under license, in a

number of therapeutic areas. Recordati's current and growing coverage of the European pharmaceutical market makes it a partner of choice for new product licenses from companies which do not have European marketing organizations. Recordati is committed to the research of new drug entities within the cardiovascular and urogenital therapeutic areas in which its research team has proven scientific competence and a track record of discovery and development of original drugs. For more information about Recordati and the Company's product pipeline, please visit [www.recordati.com](http://www.recordati.com).

About Lee's

**Lee's Pharmaceutical Holdings Limited**, a specialty biopharmaceutical company operating in China for over 14 years, was successfully listed on the Growth Enterprise Market (GEM) of the Stock Exchange of Hong Kong Limited in 2002. It is a fully integrated biopharmaceutical company with a solid infrastructure in both drug and clinical development. In addition, it carries out regulatory matters as well as manufacturing, sales and marketing activities throughout China. Lee's currently markets six products in China, and focuses its development efforts on various clinical areas, including cardiovascular and infectious diseases, dermatology, oncology, gynecology and others with more than 15 products currently at different development stages. This is the result of both internal R&D activities as well as from their recent acquisition of licensing and distribution rights from various US, Japan and European partners.

### **Safe Harbor Statement**

*The statements in this news release, other than the historical financial information, may contain forward-looking statements that involve risks and uncertainties that could cause actual results to differ from anticipated results. Further information on risk factor that could affect, among other things, Lee's financial condition and results of operations is detailed in Lee's IPO prospectus, as filed with the Growth Enterprise Market of the Stock Exchange of Hong Kong Limited.*

*For further information, please contact:*

*Vivian Fung*

*Tel: (852)2314-1282*

*Fax: (852)2314-1708*

*Email: [info@leespharm.com](mailto:info@leespharm.com)*